Skip to main content

Gen-Probe, BioMerieux Pen Three Technology Agreements

NEW YORK, Oct. 7 (GenomeWeb News) - Gen-Probe and BioMerieux have signed three agreements in which Gen-Probe will pay for access to BioMerieux's blood clot-related biomarkers for blood clotting disorders, Gen-Probe will gain negotiation rights for access to the BioMerieux Nuclisens EasyQ platform, and BioMerieux will have access to Gen-Probe's ribosomal RNA markers, said BioMerieux in a statement today.


Gen-Probe will pay $1 million to use the blood clot-related biomarkers "to develop tests that detect mutations in the genes that code for factor V and prothrombin," which are proteins that control the blood clotting process, said the statement.


Under the Nuclisens EasyQ platform arrangement, Gen-Probe may negotiate to "develop TMA amplified assays complementary to bioMerieux product lines" for further distribution by BioMerieux, the statement said.


BioMerieux will pay $250,000 for a limited research license and an option to develop diagnostic products, using Gen-Probe's ribosomal RNA markers, said BioMerieux. If the option is exercised, BioMerieux may as much as $7.5 million, "depending on the number of the targets exercised," the statement said. Under the licenses, Gen-Probe will also receive royalties on the sale of products developed using its technology, the statement added.


The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.